FORMULARY
A PEER-REVIEWED JOURNAL FOR MANAGED CARE AND HOSPITAL DECISION MAKERS

Subject Index to Volume 34, 1999

A

abacavir sulfate
  Ziagen, update on, 111 (Feb)
Academy of Managed Care Pharmacy
  formulary standards, drafting, 907 (Nov)
acarbose
  Precose, update on, 13 (Jan)
acute coronary syndromes
  glycoprotein (GP) IIb/IIIa receptor antagonists for adjunctive Tx of, 500 (Jun)
adverse drug reactions
  reporting of, in ambulatory setting, 464 (May)
AIDS
  abacavir sulfate as adjunct Tx for, 111 (Feb)
  costs of Tx for, 165 (Feb)
AIDS-related Kaposi's sarcoma
  alitretinoin gel for Tx of cutaneous lesions in, 188 (Mar)
alatrofloxacin mesylate injection
  Trovan IV, update on, 201 (Mar)
albumin
  guidelines for use of, 151 (Feb)
alendronate sodium tablets
  Fosamax, update on, 637 (Aug)
alitretinoin gel 0.1%
  Panretin, update on, 188 (Mar)
alosetron HCl
  studies with, show reduction in irritable bowel syndrome symptoms, 642 (Aug)
alteplase
  tenecteplase, compared with (abstr), 877 (Oct)
alteplase/abciximab combination
  patency rate, improves (abstr), 793 (Sep)
Alzheimer's disease
  new drugs for the Tx of, 470 (May)
  pharmacologic Tx of, 32 (Jan)
  rivastigmine for Tx of, 493 (Jun)
amifostine for injection
  Ethyol, update on, 637 (Aug)
amiodarone
  congestive heart failure, for controlling ventricular function in (abstr), 282 (Mar)
  low-dose, reduces recurrence of atrial fibrillation, 463 (May)
amlodipine
  elderly hypertensive patients, for Tx of, 371 (Apr)
amphotericin B lipid complex
  guidelines for use of, 175 (Feb)
amprenavir
  focus on, 567 (Jul)
anagrelide HCl
  Agrylin, update on, 111 (Feb)
analgesics, sedatives
  program for monitoring use of, 710 (Aug)
anaplastic astrocytoma
  refractory, temozolomide for Tx of, 812 (Oct)
anastrozole
  tamoxifen, compared with, for Tx of advanced breast cancer, 904 (Nov)
ancrod
  stroke, studied for Tx of, 366 (Apr)
anesthesia
  local and regional, levobupivacaine for, 815 (Oct)
  rapacuronium bromide as adjunct to, 810 (Oct)
angina
  dalteparin sodium injection for Tx of, 550 (Jul)
  nitrates, selecting, for Tx of, 590 (Jul)
angiotensin II receptor blockers
  formulary acceptance of, compared, 632 (Aug)
  place of, in clinical practice, 943 (Nov)
  telmisartan more effective than losartan, ambulatory BP monitoring study finds (abstr), 1053 (Dec)
angiotensin-converting enzymes
  widespread use of, justified by study, 819 (Oct)
antiarrhythmia
  dofetilide for Tx of, 895 (Nov)
antibacterial agents
  new, 880 (Oct)
antibiotic resistance
  rational formulary approach to, 664 (Aug)
  strategy for reducing, 708 (Aug)
  urinary tract infection, in Tx of, 963 (Nov)
antibiotics
  oxazolidinones are new class of, 967 (Nov)
  program for monitoring use of broad-spectrum, 873 (Oct)
  rational use of, in ICU, 836 (Oct)
antiemetics
  protocol for use of, 789 (Sep)
antihemophilic factor (human), double viral inactivation
  Koate-DVI, update on, 638 (Aug)
antihemophilic factor/von Willebrand factor complex (human)
  Humate-P, update on, 550 (Jul)
antihypertensive agents
  angiotensin receptor blockers, as, 943 (Nov)
antimicrobial resistance
  reducing, 67 (Jan)
antiplatelet agents
  formulary acceptance of, compared, 890 (Nov)
antiretroviral therapy
  preventing opportunistic infections, and, 418 (May)
antithymocyte globulin (rabbit)
  Thymoglobulin, update on, 106 (Feb)
antivirals
  newly approved, 294 (Mar)
apnea of prematurity
  caffeine citrate for Tx of, 903 (Nov)
apolipoprotein B
  cerivastatin sodium for reducing level of, 549 (Jul)
amprenavir
  Agenerase, update on, 480 (Jun)
aprotinin
  results of using high and low doses of, 171 (Feb)
  usage guidelines for, tips on team development, report of results obtained, 1048 9Dec)
arthritis
  celecoxib for Tx of, 19 (Jan); 104 (Feb); 405 (May)
  COX-2 inhibitors v NSAIDs for Tx of, 855 (Oct)
  etanercept for Tx of, 64 (Jan); 211 (Mar); 549 (Jul)
  infliximab for Tx of, 117 (Feb)
  leflunomide for Tx of, 21 (Jan)
  new drugs for Tx of, 82 (Jan)
  rofecoxib for Tx of, 19 (Jan); 549 (Jul)
astemizole tablets
  Hismanal, update on, 638 (Aug)
asthma
  budesonide, once-daily dosing of, for Tx of, 14 (Jan)
  education program for patients with, 167 (Feb)
  management program for patients with, 607 (Jul)
  new drugs for Tx of, 974 (Nov)
  treatments for, added to formularies, 95 (Feb)
atopic dermatitis
  flucinolone acetonide topical oil, 0.01%, for Tx of, 812 (Oct)
atorvastatin
  use of, in patients with stable CHD, 76 (Jan)
atrial fibrillation
  azimilide for reducing recurrences of, 76 (Jan)
  azimilide for use in, 737 (Sep)
  trandolapril for reducing incidence of after MI (abstr), 877 (Oct)
AUC/MIC ratio
  use of, in predicting fluoroquinolone therapy outcomes, 1033 (Dec)
autologous cell vaccine
  M-Vax, update on, 394 (May)
azimilide
  atrial fibrillation, for reducing recurrences of, 76 (Jan)
  focus on, 737 (Sep)

B

benign prostatic hyperplasia
  hypertension and concomitant, pharmacologic Tx of, 220 (Mar)
betamethasone valerate
  Luxiq Foam, 0.12%, update on, 307 (Apr)
biologic agents
  approval of, in 1998, 96 (Feb)
bipolar disorder
  lamotrigine for Tx of depression component of, 402 (May)
biotechnology agents
  formulary policies regarding newer, 920 (Nov)
bladder, overactive
  oxybutynin chloride for Tx of, 192 (Mar)
bone mineral density
  low-dose estrogen shown to increase, in elderly women, 644 (Aug)
bronchospasm, acute
  levalbuterol HCl for Tx, prevention of, 391 (May)
budesonide
  Pulmicort turbuhaler, update on, 14 (Jan)
budenoside nasal spray
  Rhinocort Aqua, update on, 903 (Nov)
buffered regular human insulin injection (rDNA origin)
  Velosulin BR, update on, 728 (Sep)
busulfan
  Busulfex Injection, update on, 192 (Mar)

C

caffeine citrate injection
  Cafcit, update on, 903 (Nov)
calfactant intratracheal suspension
  Infasurf, update on, 987 (Dec)
cancer
  breast
    anastrozole v tamoxifen as Tx for advanced, 904 (Nov)
    epirubicin for Tx of node-positive, 892 (Nov)
  cervical
    cisplatin-containing chemotherapy for Tx of, 308 (Apr)
  colon, stage II
    OncoVAX studied for improving survival after, 204 (Mar)
  nonsmall cell lung
    porfimer sodium for Tx of, 115 (Feb)
  ovarian
    doxorubicin HCl for Tx of metastatic, 725 (Sep)
  prostate
    LHRH antagonists compared for Tx of, 208 (Mar)
    new drugs for Tx of, 714 (Aug)
  small cell lung
    topotecan HCl for Tx of, 190 (Mar)
  thyroid
    thyrotropin alfa for use in screening for, 106 (Feb)
cancers, female-associated
  new drugs for Tx of, 622 (Jul)
cancers, various
  new drugs for Tx of, 796 (Sep)
candidiasis, vaginal
  fluconazole most cost-effective Tx for, 278 (Mar)
capecitabine
  Xeloda, update on, 552 (Jul)
case management
  depression, of, by clinical pharmacists, 864 (Oct)
cefpodoxime proxetil

FORMULARY
A PEER-REVIEWED JOURNAL FOR MANAGED CARE AND HOSPITAL DECISION MAKERS

Subject Index to Volume 34, 1999

A

abacavir sulfate
  Ziagen, update on, 111 (Feb)
Academy of Managed Care Pharmacy
  formulary standards, drafting, 907 (Nov)
acarbose
  Precose, update on, 13 (Jan)
acute coronary syndromes
  glycoprotein (GP) IIb/IIIa receptor antagonists for adjunctive Tx of, 500 (Jun)
adverse drug reactions
  reporting of, in ambulatory setting, 464 (May)
AIDS
  abacavir sulfate as adjunct Tx for, 111 (Feb)
  costs of Tx for, 165 (Feb)
AIDS-related Kaposi's sarcoma
  alitretinoin gel for Tx of cutaneous lesions in, 188 (Mar)
alatrofloxacin mesylate injection
  Trovan IV, update on, 201 (Mar)
albumin
  guidelines for use of, 151 (Feb)
alendronate sodium tablets
  Fosamax, update on, 637 (Aug)
alitretinoin gel 0.1%
  Panretin, update on, 188 (Mar)
alosetron HCl
  studies with, show reduction in irritable bowel syndrome symptoms, 642 (Aug)
alteplase
  tenecteplase, compared with (abstr), 877 (Oct)
alteplase/abciximab combination
  patency rate, improves (abstr), 793 (Sep)
Alzheimer's disease
  new drugs for the Tx of, 470 (May)
  pharmacologic Tx of, 32 (Jan)
  rivastigmine for Tx of, 493 (Jun)
amifostine for injection
  Ethyol, update on, 637 (Aug)
amiodarone
  congestive heart failure, for controlling ventricular function in (abstr), 282 (Mar)
  low-dose, reduces recurrence of atrial fibrillation, 463 (May)
amlodipine
  elderly hypertensive patients, for Tx of, 371 (Apr)
amphotericin B lipid complex
  guidelines for use of, 175 (Feb)
amprenavir
  focus on, 567 (Jul)
anagrelide HCl
  Agrylin, update on, 111 (Feb)
analgesics, sedatives
  program for monitoring use of, 710 (Aug)
anaplastic astrocytoma
  refractory, temozolomide for Tx of, 812 (Oct)
anastrozole
  tamoxifen, compared with, for Tx of advanced breast cancer, 904 (Nov)
ancrod
  stroke, studied for Tx of, 366 (Apr)
anesthesia
  local and regional, levobupivacaine for, 815 (Oct)
  rapacuronium bromide as adjunct to, 810 (Oct)
angina
  dalteparin sodium injection for Tx of, 550 (Jul)
  nitrates, selecting, for Tx of, 590 (Jul)
angiotensin II receptor blockers
  formulary acceptance of, compared, 632 (Aug)
  place of, in clinical practice, 943 (Nov)
  telmisartan more effective than losartan, ambulatory BP monitoring study finds (abstr), 1053 (Dec)
angiotensin-converting enzymes
  widespread use of, justified by study, 819 (Oct)
antiarrhythmia
  dofetilide for Tx of, 895 (Nov)
antibacterial agents
  new, 880 (Oct)
antibiotic resistance
  rational formulary approach to, 664 (Aug)
  strategy for reducing, 708 (Aug)
  urinary tract infection, in Tx of, 963 (Nov)
antibiotics
  oxazolidinones are new class of, 967 (Nov)
  program for monitoring use of broad-spectrum, 873 (Oct)
  rational use of, in ICU, 836 (Oct)
antiemetics
  protocol for use of, 789 (Sep)
antihemophilic factor (human), double viral inactivation
  Koate-DVI, update on, 638 (Aug)
antihemophilic factor/von Willebrand factor complex (human)
  Humate-P, update on, 550 (Jul)
antihypertensive agents
  angiotensin receptor blockers, as, 943 (Nov)
antimicrobial resistance
  reducing, 67 (Jan)
antiplatelet agents
  formulary acceptance of, compared, 890 (Nov)
antiretroviral therapy
  preventing opportunistic infections, and, 418 (May)
antithymocyte globulin (rabbit)
  Thymoglobulin, update on, 106 (Feb)
antivirals
  newly approved, 294 (Mar)
apnea of prematurity
  caffeine citrate for Tx of, 903 (Nov)
apolipoprotein B
  cerivastatin sodium for reducing level of, 549 (Jul)
amprenavir
  Agenerase, update on, 480 (Jun)
aprotinin
  results of using high and low doses of, 171 (Feb)
  usage guidelines for, tips on team development, report of results obtained, 1048 9Dec)
arthritis
  celecoxib for Tx of, 19 (Jan); 104 (Feb); 405 (May)
  COX-2 inhibitors v NSAIDs for Tx of, 855 (Oct)
  etanercept for Tx of, 64 (Jan); 211 (Mar); 549 (Jul)
  infliximab for Tx of, 117 (Feb)
  leflunomide for Tx of, 21 (Jan)
  new drugs for Tx of, 82 (Jan)
  rofecoxib for Tx of, 19 (Jan); 549 (Jul)
astemizole tablets
  Hismanal, update on, 638 (Aug)
asthma
  budesonide, once-daily dosing of, for Tx of, 14 (Jan)
  education program for patients with, 167 (Feb)
  management program for patients with, 607 (Jul)
  new drugs for Tx of, 974 (Nov)
  treatments for, added to formularies, 95 (Feb)
atopic dermatitis
  flucinolone acetonide topical oil, 0.01%, for Tx of, 812 (Oct)
atorvastatin
  use of, in patients with stable CHD, 76 (Jan)
atrial fibrillation
  azimilide for reducing recurrences of, 76 (Jan)
  azimilide for use in, 737 (Sep)
  trandolapril for reducing incidence of after MI (abstr), 877 (Oct)
AUC/MIC ratio
  use of, in predicting fluoroquinolone therapy outcomes, 1033 (Dec)
autologous cell vaccine
  M-Vax, update on, 394 (May)
azimilide
  atrial fibrillation, for reducing recurrences of, 76 (Jan)
  focus on, 737 (Sep)

B

benign prostatic hyperplasia
  hypertension and concomitant, pharmacologic Tx of, 220 (Mar)
betamethasone valerate
  Luxiq Foam, 0.12%, update on, 307 (Apr)
biologic agents
  approval of, in 1998, 96 (Feb)
bipolar disorder
  lamotrigine for Tx of depression component of, 402 (May)
biotechnology agents
  formulary policies regarding newer, 920 (Nov)
bladder, overactive
  oxybutynin chloride for Tx of, 192 (Mar)
bone mineral density
  low-dose estrogen shown to increase, in elderly women, 644 (Aug)
bronchospasm, acute
  levalbuterol HCl for Tx, prevention of, 391 (May)
budesonide
  Pulmicort turbuhaler, update on, 14 (Jan)
budenoside nasal spray
  Rhinocort Aqua, update on, 903 (Nov)
buffered regular human insulin injection (rDNA origin)
  Velosulin BR, update on, 728 (Sep)
busulfan
  Busulfex Injection, update on, 192 (Mar)

C

caffeine citrate injection
  Cafcit, update on, 903 (Nov)
calfactant intratracheal suspension
  Infasurf, update on, 987 (Dec)
cancer
  breast
    anastrozole v tamoxifen as Tx for advanced, 904 (Nov)
    epirubicin for Tx of node-positive, 892 (Nov)
  cervical
    cisplatin-containing chemotherapy for Tx of, 308 (Apr)
  colon, stage II
    OncoVAX studied for improving survival after, 204 (Mar)
  nonsmall cell lung
    porfimer sodium for Tx of, 115 (Feb)
  ovarian
    doxorubicin HCl for Tx of metastatic, 725 (Sep)
  prostate
    LHRH antagonists compared for Tx of, 208 (Mar)
    new drugs for Tx of, 714 (Aug)
  small cell lung
    topotecan HCl for Tx of, 190 (Mar)
  thyroid
    thyrotropin alfa for use in screening for, 106 (Feb)
cancers, female-associated
  new drugs for Tx of, 622 (Jul)
cancers, various
  new drugs for Tx of, 796 (Sep)
candidiasis, vaginal
  fluconazole most cost-effective Tx for, 278 (Mar)
capecitabine
  Xeloda, update on, 552 (Jul)
case management
  depression, of, by clinical pharmacists, 864 (Oct)
cefpodoxime proxetil

Vantin, update on, 116 (Feb)
cefuroxime, continuous infusion
community-acquired pneumonia, for Tx of (abstr), 282 (Mar)
celecoxib
arthritis, for Tx of, 19 (Jan)
Celebrex, update on, 104 (Feb); 638 (Aug)
focus on, 405 (May)
cerivastatin sodium
Baycol, update on, 549 (Jul)
cervical ripening
misoprostol for, 77 (Jan)
cholesterol, HDL
simvastatin tablets for raising, 815 (Oct)
cholesterol, LDL
amount of reduction needed in levels of, 462 (May)
chronic obstructive pulmonary disease
ipratropium for Tx of, 492 (Jun)
new drugs for Tx of, 974 (Nov)
cigarette smoking
effect of, on warfarin dosing and pharmacokinetics, 873 (Oct)
cilostazol
Pletal, update on, 190 (Mar)
cisplatin-containing chemotherapy
cervical cancer, for Tx of, 308 (Apr)
clindamycin phosphate
Cleocin Vaginal Ovules, update on, 728 (Sep)
clopidogrel
ticlodipine, compared with, 461 (May)
CMV immune globulin (human)
CytoGam, update on, 112 (Feb)
congestive heart failure
amiodarone for controlling ventricular function in (abstr), 282 (Mar)
congestive heart failure, decompensated
nesiritide for use in patients with, 123 (Feb)
new drugs investigated for Tx of, 276 (Mar)
spironolactone for use in, 752 (Sep)
conjugated estrogen, A (synthetic)
Cenestin, update on, 392 (May)
contraception
levonorgestrol 0.75-mg tablets for emergency, 726 (Sep)
coronary heart disease
gemfibrozil for reducing cardiac events in, 75 (Jan)
lovastatin for primary prevention of, 487 (Jun)
stable, atorvastatin for lipid lowering in patients with, 76 (Jan)
COX-2 inhibitors
NSAIDs, compared with, for Tx of arthritis, 855 (Oct)
cytarabine liposome injection
DepoCyt, update on, 487 (Jun)
cytomegalovirus disease
CMV immune globulin (human) for prophylaxis against, 112 (Feb)

D

dalteparin sodium injection
Fragmin, update on, 482 (Jun); 550 (Jul)
deep vein thrombosis
dalteparin sodium for prophylaxis against, in hip replacement surgery, 482 (Jun)
economic and QOL gains seen with outpatient LMWH Tx (abstr), 1053 (Dec)
dementia
severe, memantine studied for Tx of, 491 (Jun)
denileukin diftitox
Ontak, update on, 188 (Mar)
depression
case management of, by clinical pharmacists, 864 (Oct)
costs of serotonin reuptake inhibitors for Tx of, 578 (Jul)
evaluating cost-effectiveness of drugs for Tx of major, 683 (Aug)
new drugs for Tx of, 378 (Apr)
paroxetine HCl for Tx of, 307 (Apr)
reboxetine, for Tx of, 909 (Nov)
diabetes
new drugs for Tx of, 178 (Feb)
diabetes, type 1
insulin aspart, insulin glargine, studied for Tx of, 729 (Sep)
diabetes, type 2
acarbose as adjunct for Tx of, 13 (Jan)
nateglinide shows promise for Tx of, 996 (Dec)
pioglitazone HCl for Tx of, 724 (Sep)
rosiglitazone maleate for Tx of, 546 (Jul); 825 (Oct)
dialysis
sodium ferric gluconate for patients on, 304 (Apr)
dietary supplements
FDA policy on, considered, 972 (Nov)
disease management program
assessing and reporting outcomes of, 455 (May)
developing, in large health system, 168 (Feb)
dofetilde capsules
Tikosyn, update on, 895 (Nov)
doxercalciferol capsules
Hectorol, update on, 634 (Aug)
doxorubicin HCl
Doxil, update on, 725 (Sep)
doxorubicin, liposomal
reduced cardiac toxicity with, 121 (Feb)
doxycycline
community-acquired pneumonia, as inpatient Tx for, 310 (Apr)
drug advertising
controversy regarding, 878 (Oct)
managed care organizations and, 117 (Feb)
drug approvals
new, in 1998, 96 (Feb)
drug benefit
costs of, reach record level, 729 (Sep)
drug copayments
effect on drug use, and, 400 (May)
drug costs
guideline enforcement, and, 257 (Mar)
HMOs and controlling, 203 (Mar)
newer agents for depression, sinusitis, of, 400 (May)
reduction in, from use of generics, 641 (Aug)
drug safety
concerns about, 373 (Apr)
drug samples
policy on, 78 (Jan)
dry mouth
amifostine for relief of, in some patients undergoing head/neck radiation therapy, 637 (Aug)

E

ebastine
focus on, 645 (Aug)
seasonal allergic rhinitis, for Tx of, 488 (Jun)
electronic point-of-care prescribing
benefits of, steps for, 68 (Jan)
eletriptan
migraine, studied for Tx of, 819 (Oct)
endometrial hyperplasia
progesterone for prevention of, in patients on estrogen, 116 (Feb)
entacapone
Comtan, update on, 987 (Dec)
epirubicin HCl injection
Ellence, update on, 892 (Nov)
eprosartan mesylate
Teveten, update on, 988 (Dec)
erythropoietin
guidelines for use in premature infants helpful, 531 (Jun)
estradiol/norethindrone acetate
Activelle, update on, 14 (Jan)
estradiol vaginal tablet
Vagifem, update on, 394 (May)
estrogen
low-dose, shows bone-sparing effects in elderly women, 644 (Aug)
etanercept
Enbrel, update on, 549 (Jul)
focus on, 211 (Mar)
exemestane
Aromasin, update on, 984 (Dec)

F

famotidine
Pepcid, update on, 115 (Feb)
FDA
dietary supplements, policy for considered, 972 (Nov)
pediatric labeling initiatives, 534 (Jun)
FDA Modernization Act
implementation of, 176 (Feb)
fentanyl citrate
Actiq, update on, 13 (Jan)
flucinolone acetonide topical oil, 0.01%
Derma-Smoothe/FS, update on, 812 (Oct)
fluconazole
vaginal candidiasis, most cost-effective Tx for, 278 (Mar)
fluoroquinolone therapy outcomes
potential role of the AUC/MIC ratio in predicting, 1033, (Dec)
fluoxetine HCl
Prozac, update on, 990 (Dec)
fluticasone propionate
Flonase, update on, 112 (Feb)
Flovent, update on, 201 (Mar)
fluticasone propionate cream, 0.05%
Cutivate Cream, update on, 634 (Aug)
flu vaccine
intranasal, studied, 207 (Mar)
fluvastatin sodium
Lescol, update on, 304 (Apr)
formulary(ies)
ACMP drafting standards for, 907 (Nov)
alternative medicines, adding to, in MCO, 704 (Aug)
asthma treatments included on, 95 (Feb)
biotechnology agents, policies regarding newer, 920 (Nov)
decision making, team for, 618 (Jul)
key factors in changing, 617 (Jul)
revising review process for, 704 (Aug)
PPO acceptance of, 20 (Jan)
software for, 269 (Mar)
systemwide, lessons on, 159 (Feb)
team approach to evaluating, 47 (Jan)

G

gabapentin
chronic neuropathic pain, for Tx of, 118 (Feb)
ganirelix acetate injection
Antagon, update on, 724 (Sep)
gastroesophageal reflux disease
famotidine for Tx of, in children, 115 (Feb)
rabeprazole for Tx of, 20 (Jan)
stepwise approach to managing, 234 (Mar)
gastrointestinal disorders
new drugs for Tx of, 536 (Jun)
gatifloxacin
focus on, 1002 (Dec)
gemfibrozil
coronary heart disease, for reducing cardiac events in, 75 (Jan)
generalized anxiety disorder
venlafaxine HCl for Tx of, 482 (Jun)
generics
cost savings from use of, 641 (Aug)
geriatric pharmacotherapy guidelines
developing, 764 (Sep)
glaucoma
cost-minimization analysis in choosing therapy for, 613 (Jul)
latanoprost for Tx of, 822 (Oct)
glycoprotein (GP) IIb/IIIa receptor antagonists
acute coronary syndromes, as adjunct in Tx of, 500 (Jun)
evaluating cost-effectiveness of, 515 (Jun)
granisetron HCl tablets
Kytril, update on, 726 (Sep)
grepafloxacin HCl
Raxar, update on, 995 (Dec)

H

5-HT_1 receptor antagonists
formulary acceptance of, compared, 632 (Aug)
5-HT_3 receptor antagonists

formulary acceptance of, compared, 890 (Nov)
H_2-receptor antagonists
as example of a successful Rx-to-OTC switch, 452 (May)
HAART
eliminates need for MAC, PCP prophylaxis in some patients, 967 (Nov)
heart failure
nesiritide for Tx of acute, 70 (Jan)
severe congestive, spironolactone for Tx of, 75 (Jan)
severe decompensated, levosimendan for Tx of, 904 (Nov)
systolic, four-drug regimen for Tx of, in stable, 202 (Mar)
Helicobacter pylori
diagnosis and treatment of, 654 (Aug)
hematopoietic progenitor cell transplantation
busulfan, use of, before, 192 (Mar)
hemophilia
recombinant human coagulation factor VIIa for Tx of bleeding episodes in, 391 (May)
hemophilia A
antihemophilic factor (human), double viral inactivation, for Tx of, 638 (Aug)
heparin, low molecular weight
evaluating use of, in a health system, 144 (Feb)
hepatitis A
vaccination for, 310 (Apr)
hepatitis A immune globulin (human)
Nabi-HB, update on, 392 (May)
hepatitis B infection
interferon alfa/famciclovir for Tx of chronic (abstr), 284 (Mar)
lamivudine for Tx of, 112 (Feb)
hepatitis C infection
IFN alfa-2b, ribavirin combination for Tx of chronic, 116 (Feb)
interferon for Tx of, 87 (Feb)
interferon alfa-n1 for Tx of chronic, 552 (Jul)
herbal products
best, for including in health care benefit package, 530 (Jun)
consideration for formulary inclusion of, 77 (Jan)
integrating, into managed care, 607 (Jul)
liability issues associated with, in managed care organizations 525 (Jun)
HIV infection
amprenavir for use in Tx of, 480 (Jun); 567 (Jul)
MAC and PCP prophylaxis not need in patients with, if responsive to HAART, 967 (Nov)
HMG CoA-reductase inhibitor(s)
critical evaluation of a cost-effectiveness analysis involving, 1041 (Dec)
improves lipid lowering in combination with HRT (abstr), 284 (Mar)
standards for timing initiation of, debated, 908 (Nov)
HMOs
California, investigated, 308 (Apr)
survey shows challenges of, 203 (Mar)
survey shows percent successful at influencing prescribing, 996 (Dec)
hormone replacement therapy
heart disease, in women with existing, 463 (May)
hormone surges
ganirelix acetate for inhibiting, during fertility Tx, 724 (Sep)
HTF-919
irritable bowel syndrome symptoms, shown to reduce, 642 (Aug)
human coagulation factor VIIa, recombinant
NovoSeven, update on, 391 (May)
hyperparathyroidism
doxercalciferol for management of, in chronic renal failure, 634 (Aug)
hypertension
benign prostatic hyperplasia and concomitant, Tx of, 220 (Mar)
options for Tx of, 614 (Jul)
temisartan for Tx of, 13 (Jan)
verapamil HCl for Tx of, 194 (Mar)

I

IFN alfa-2b, ribavirin combination
Rebetron, update on, 116 (Feb)
immune globulin, intravenous
measures taken to reduce use, cost of, 464 (May)
immunomodulators
newly approved, 294 (Mar)
infections, serious bloodstream and skin
quinupristin/dalfopristin for Tx of, 895 (Nov)
infectious disease approval service
pharmacist-managed, 275 (Mar)
infliximab
rheumatoid arthritis, for Tx of, 117 (Feb)
influenza
zanamivir for prevention of, 963 (Nov)
zanamivir for Tx of, 725 (Sep)
information systems, healthcare
keys to success of, 160 (Feb)
injectables
MCO eye managed programs in quest for cost savings, 998 (Dec)
insomnia
zaleplon for Tx of, 810 (Oct)
insulin aspart, insulin glargine
type 1 diabetes, studied for Tx of, 729 (Sep)
intensive care unit
rational use of antibiotics in, 836 (Oct)
interferon
evaluation of, for Tx of hepatitis C infection, 132 (Feb)
interferon alfa/famciclovir
chronic hepatitis B, for Tx of (abstr), 284 (Mar)
interferon alfa-n1
Wellferon, update on, 552 (Jul)
intermittent claudication
cilostazol for reducing symptoms of, 190 (Mar)
ipratropium
chronic obstructive pulmonary disease, for Tx of, 492 (Jun)
irritable bowel syndrome
alosetron HCl shown to reduce symptoms of, 642 (Aug)
HTF 919 shown to reduce symptoms of, 642 (Aug)
itraconazole
Sporanox Injection, update on, 394 (May)

K

ketorolac/chlorpromazine combination
chronic pain, relieves exacerbations of, 733 (Sep)
ketotifen fumarate ophthalmic solution, 0.025%
Zaditor, update on, 725 (Sep)
kidney transplant rejection
sirolimus oral solution for prevention of, 892 (Nov)

L

lamivudine
Epivir-HBV, update on, 112 (Feb)
lamotrigine
depression component of bipolar disorder, for Tx of, 402 (May)
Lamictal, update on, 115 (Feb)
lanoteplase
studied, for the Tx of myocardial infarction, 461 (May)
latanoprost
glaucoma, for Tx of, 822 (Oct)
leflunomide
focus on, 21 (Jan)
levalbuterol HCl
Xopenex, update on, 391 (May)
levobupivacaine injection
Chirocaine, update on, 815 (Oct)
levonorgestrel 0.75-mg tablets
Plan B, update on, 726 (Sep)
levosimendan
dobutamine, compared with, for Tx of heart failure, 904 (Nov)
lidocaine patch 5%
Lidoderm, update on, 487 (Jun)
lifestyle drugs
decisions regarding, 58 (Jan)
liver damage
tolcapones potential for, 16 (Jan)
lovastatin
Mevacor, update on, 487 (Jun)
Lyme disease
vaccine for immunization against, 104 (Feb)
lymphoma, cutaneous T-cell
denileukin diftitox for Tx of, 188 (Mar)

M

managed care
controlling drug costs, and, 529 (Jun)
coverage of herbal products, liability associated with, 515 (Jun)
drug advertising, and, 117 (Feb)
physician leadership in, ensuring, 526 (Jun)
policy on reform of, 80 (Jan)
maxillary sinusitis
cefpodoxime proxetil for Tx of acute, 116 (Feb)
medical records
electronic, 52 (Jan)
Medicare
capitation, 515 (Jun)
drug debate, 289 (Mar)
policy on, 80 (Jan)
medication assistance program
indigent patients, for, 171 (Feb)
memantine
severe dementia, studied for Tx of, 491 (Jun)
menopause symptoms
estradiol/norethindrone acetate for Tx of, 14 (Jan)
synthetic conjugated estrogens, A, for Tx of, 392 (May)
menotropins for injection, USP
Repronex, update on, 903 (Nov)
metronidazole lotion
MetroLotion, update on, 192 (Mar)
migraine
eletriptan studied for Tx of, 819 (Oct)
limiting use of therapies for, 970 (Nov)
new agents for Tx of, compared, 324 (Apr)
misoprostol
cervical ripening, for, 77 (Jan)
modafinil
Provigil, update on, 106 (Feb)
montelukast sodium
Singulair, update on, 201 (Mar)
mupirocin
preoperative intranasal, lowers risk of *S aureus* infection, 488 (Jun)
mupirocin ointment 2%
Bactroban, update on, 552 (Jul)
mycophenolate mofetil
CellCept, update on, 14 (Jan)
myeloma, multiple
thalidomide for Tx of, 201 (Mar)
myocardial infarction
lanoteplase and tenecteplase studied for Tx of, 461 (May)
non-Q-wave, dalteparin sodium for Tx of, 550 (Jul)

N

naratriptan
migraine, for Tx of, 324 (Apr)
narcolepsy
modafinil for Tx of, 106 (Feb)
nausea, vomiting
granisetron HCl for prevention of, 726 (Sep)
ondansetron HCl for prevention of, 307 (Apr); 815 (Oct)
nesiritide
acute heart failure, for Tx of, 70 (Jan)
focus on, 87 (Feb)
neuromuscular blocking agents
algorithm for use of, 970 (Nov)
neuropathic pain, chronic
gabapentin for Tx of, 118 (Feb)
niacin extended-release tablets
Niaspan, update on, 990 (Dec)nitrates
selection of, for Tx of angina, 590 (Jul)
norethindrone acetate/ethinyl estradiol tablets
FEMHRT 1/5, update on, 990 (Dec)
NSAIDs

PPIs heal, prevent NSAID-induced ulcers, 1001 (Dec)
use of, in nursing homes, 531 (Jun)

O

obesity
orlistat for weight loss management in, 482 (Jun)
octreotide acetate
Sandostatin LAR Depot, update on, 194 (Mar)
ocular itching
ketotifen fumarate ophthalmic solution, 0.025%, for prevention of, 725 (Sep)
ofloxacin
program for converting from IV to po, 688 (Aug)
omapatrilat
systolic blood pressure, studied for reducing, 641 (Aug)
omeprazole
stress ulcer, as prophylaxis against, 274 (Mar)
ondansetron HCl
Zofran ODT, update on, 307 (Apr)
ondansetron HCl tablets
Zofran, update on, 815 (Oct)
online pharmacies
concerns about, 468 (May)
opioid agonists/antagonists
formulary changes regarding, 792 (Sep)
orlistat
Xenical, update on, 482 (Jun)
oseltamivir phosphate
Tamiflu, update on, 988 (Dec)
OspA, recombinant
LYMErix, update on, 104 (Feb)
osteoporosis
drugs for Tx of, compared, 388 (May)
glucocorticoid-induced, alendronate for Tx of, 637 (Aug)
raloxifene for Tx of, 896 (Nov)
otitis media
cefpodoxime proxetil for Tx of acute, 116 (Feb)
outcomes
assessment of, in routine practice, 52 (Jan)
management, future of, 776 (Sep)
patients surveys for obtaining data regarding, 165 (Feb)
research, tips on, 158 (Feb)
research, translating, into clinical practice, 251 (Mar)
studies, evaluating quality and applicability of, 603 (Jul)
oxazolidinones
antibiotics, new class of, 967 (Nov)
oxybutynin chloride
Ditropan XL, update on, 192 (Mar)

P

P & T Committee
reorganization of, 47 (Jan)
restructuring of, 341 (Apr)
trends in responsibilities of, 273 (Mar)
paclitaxel injection
Taxol, update on, 990 (Dec)
pain, acute
program for management of, 619 (Jul)
pain, chronic
ketorolac/chlorpromazine combination for Tx of, 733 (Sep)
pain management, postoperative
levobupivacaine for, 815 (Oct)
Parkinson's disease
pergolide for Tx of early (abstr), 793 (Sep)
ropinirole for Tx of early, 733 (Sep)
ropinirole, update on, 995 (Dec)
paroxetine HCl
Paxil CR, update on, 307 (Apr); 550 (Jul)
patient rights
access to needed medications, and, 794 (Sep)
pediatric labeling initiatives
FDA, 534 (Jun)
pergolide
early stage Parkinsons disease, for effective Tx of (abstr), 793 (Sep)
perindopril erbumine
Aceon, update on, 984 (Dec)
pharmaceutical prices
policy on, 80 (Jan)
pharmacist-run clinics
obtaining physician support for, 159 (Feb)
pharmacy benefits
management companies, and Medicare drug benefit, 712 (Aug)
management company, and contracts with health care plans, 269 (Mar)
PPOs and, 20 (Jan)
pioglitazone HCl tablets
Actos, update on, 724 (Sep)
piperacillin-tazobactam
nosocomial pneumonia, for Tx of (abstr), 283 (Mar)
pleconaril
enteroviral infections, for Tx of, 964 (Nov)
pneumococcal vaccination
emergency room, savings with, 402 (May)
pneumonia, community-acquired
continuous cefuroxime infusion for Tx of (abstr), 282 (Mar)
doxycycline as inpatient Tx for, 310 (Apr)
gatifloxacin, for Tx of, 1002 (Dec)
pneumonia, nosocomial
piperacillin-tazobactam for Tx of (abstr), 283 (Mar)
porfimer sodium
Photofrin, update on, 115 (Feb)
postherpetic neuralgia
lidocaine patch for Tx of, 487 (Jun)
preferred-provider organizations
pharmacy benefits, formularies, and, 20 (Jan)
prescription denials
physicians report frequent, 734 (Sep)
prescription errors
quality initiative reduces, 790 (Sep), 995 (Dec)
progesterone
Prometrium, update on, 116 (Feb)
proton pump inhibitors
efficacy and safety of, 437 (May)
MUE, criteria for use, education help improve use and expenditures of, 1052 (Dec)
prourokinase, recombinant
severe ischemic stroke, improves therapeutic window in, 365 (Apr)
psoriasis, scalp
betamethasone valerate for Tx of, 307 (Apr)
pulmonary embolism
bleeding risk associated with thrombolytic therapy for (abstr), 283 (Mar)
pulmonary masses
technetium Tc 99m depreotide for imaging of, 810 (Oct)

Q

quinupristin/dalfopristin powder for injection
Synercid I.V., update on, 895 (Nov)

R

rabeprazole sodium
Aciphex, update on, 808 (Oct)
ulcers and GERD, for Tx of, 20 (Jan)
raloxifene HCl tablets
Evista, update on, 896 (Nov)
reboxetine
depression, for Tx of major, 909 (Nov)
rapacuronium bromide for injection
Raplon, update on, 810 (Oct)
renal disease, end stage
sevelamer HCl for Tx of patients with, 10 (Jan)
renal transplant rejection
antithymocyte globulin (rabbit) for Tx of, 106 (Feb)
rhinitis, allergic
assessment of pharmacotherapeutic options for, 1016 (Dec)
ebastine for Tx of, 488 (Jun); 645 (Aug)
rhinitis, perennial/nonallergenic
fluticasone propionate for Tx of, 112 (Feb)
ritonavir
Norvir, update on, 638 (Aug)
rituximab
Rituxan, update on, 201 (Mar)
rivastigmine
focus on, 493 (Jun)
rizatriptan
migraine, for Tx of, 313 (Apr)
rofecoxib
arthritis, for Tx of, 19 (Jan)
Vioxx, update on, 549 (Jul)
ropinirole
early Parkinson's disease, for Tx of, 733 (Sep)
rosacea
metronidazole lotion for Tx of lesions of, 192 (Mar)
rosiglitazone maleate
Avandia, update on, 546 (Jul)
focus on, 825 (Oct)

S

seizures,
partial
lamitrogine for Tx of, 115 (Feb)
partial-onset
topiramate for Tx of, 16 (Jan)
tonic-clonic
topiramate for Tx of, 896 (Nov)
serotonin reuptake inhibitors
compared, 278 (Mar)
costs of and cost drivers for, assessing, 578 (Jul)
sevelamer HCl
Renagel, update on, 10 (Jan)
sildenafil
payment for, in Calif., 121 (Feb)
simethicone-coated cellulose suspension
SonoRx, update on, 10 (Jan)
simvastatin tablets
Zocor, update on, 815 (Oct)
sirolimus oral solution
Rapamune, update on, 892 (Nov)
social anxiety disorder
paroxetine HCl for Tx of, 550 (Jul)
sodium ferric gluconate
Ferrlecit, update on, 304 (Apr)
spironolactone
congestive heart failure, for Tx of, 75 (Jan); 752 (Sep)
stroke
ancrod studied for Tx of, 366 (Apr)
prourokinase improves therapeutic window in, 365 (Apr)
tissue plasminogen activator, timing of, in Tx of, 366 (Apr)

T

technetium Tc 99m depreotide injection, kit for preparation of
NeoTect, update on, 810 (Oct)
telmisartan
Micardis, update on, 13 (Jan)
temozolomide capsules
Temodar, update on, 812 (Oct)
tenecteplase
alteplase, compared with (abstr), 877 (Oct)
studied, for the Tx of myocardial infarction, 461 (May)
terbinafine gel, 1%
Lamsil DermGel, update on, 815 (Oct)
thalidomide
Thalomid, update on, 201 (Mar)
thrombocythemia
anagrelide HCl for Tx of, 111 (Feb)
thrombolytic therapy
bleeding risk from, in Tx of pulmonary embolism (abstr), 283
thyrotropin alfa
Thyrogen, update on, 106 (Feb)
tinea cruris
tebinafine gell, 1%, for Tx of, 815 (Oct)
tirofiban
test shows who will benefit from Tx with, 820 (Oct)
tissue plasminogen activator

Subject Index to Volume 34, 1999

timing of, in Tx of stroke, 366 (Apr)
tolcapone
Tasmar, update on, 16 (Jan)
topiramate
Topamax, update on, 16 (Jan); 726 (Sep); 896 (Nov)
topotecan HCl
Hycamtin, update on, 190 (Mar)
trandolapril
atrial fibrillation, for reduction of (abstr), 877 (Oct)
triglyceride
cerivastatin sodium for lowering levels of, 549 (Jul)
trovafloxacin, alatrofloxacin mesylate
Trovan, Trovan IV, update on, 638 (Aug)

U

ulcers
famotidine for Tx of, in children, 115 (Feb)
duodenal
selecting regimens for Tx of, 355 (Apr)
duodenal and gastric
rabeprazole for Tx of, 20 (Jan)
NSAID-induced
PPI heals, prevents, 1001 (Dec)
stress
omeprazole as prophylaxis against, 274 (Mar)
ultrasound imaging
simethicone-coated cellulose suspension for use in, 10 (Jan)
urinary tract infection
cost-effective regimens for Tx of uncomplicated, 371 (Apr)
problem of antibiotic resistance in, 963 (Nov)
urokinase
Abbokinase, update on, 194 (Mar)

V

vancomycin
improving appropriate use of, 711 (Aug)
vascular disease
ACE inhibitors shown effective in Tx of, 819 (Oct)
venlafaxine HCl
Effexor XR, update on, 482 (Jun)
Verapamil HCl
Verelan PM, update on, 194 (Mar)
von Willebrand disease
antihemophilic factor/von Willegrand factor complex (human) for Tx of, 550 (Jul)

W

warfarin
celecoxib, bleeding risk of, when taken with, 638 (Aug)
dosing and pharmacokinetics of, effects of cigarette smoking on, 873 (Oct)

Y

Y2K readiness
pharmacists, healh organizations, and, 620 (Jul)

Z

zafirlukast minitablets
Accolate, update on, 896 (Nov)
zaleplon capsules
Sonata, update on, 810 (Oct)
zanamivir for oral inhalation
influenza, for prophylaxis against, 963 (Nov)
Relenza, update on, 725 (Sep)
zolmitriptan
migraine, for Tx of, 313 (Apr)

Author Index to Volume 34, 1999

A

Aberg, Judith A.: Prophylaxis of opportunistic infections in the era of potent antiretroviral therapy: An update, 418 (May)
Amato, Paul V.: Domenichini, David: Focus on rosiglitazone: A new agent of the thiazolidinedione class for treatment of the type 2 diabetic patient, 825 (Oct)
Ament, Paul W.: Predicting fluoroquinolone therapy outcomes: Potential role of the AUC/MIC ratio, 1033 (Dec)
Armstrong, Edward P.:
Critical evaluation of a decision-analytic model of major depression treatment, 683 (Aug)
Evaluating low molecular weight heparins within a health system: Issues and strategies, 144 (Feb)
Aull, Meredith J.; Sanoski, Cynthia A.: Optimizing inhibition of aldosterone: Use of spironolactone in chronic heart failure, 752 (Sep)

B

Baran, Robert: See Tangalos, Eric G.
Bataoel, James R.: See Motheral, Brenda
Belliveau, Paul: See Stirling, Alexandra L.
Bercume, Roland: See Stirling, Alexandra L.
Black, Henry R.; Jacobson, Edwin J.: Angiotensin receptor blockers: Their current and future place in clinical practice, 943 (Nov)
Blitz, Susan G.: See Fendrick, A. Mark
Boyce, Eric G; Breen, Gail A.: Focus on celecoxib: A COX-2 inhibitor for the treatment of osteoarthritis and rheumatoid arthritis, 405 (May)
Branch, Robert A.: See Coley, Kim C.
Breen, Gail A.: See Boyce, Eric G.

C

Cappa, Joseph: See Feret, Brett
Chen, Bonnie P.; Chow, Moses S.S.: Proton pump inhibitors: An assessment of efficacy and safety, 437 (May)
Chow, Moses S.S.:
See Chen, Bonnie P.
See Dunn, Alisha
Coley, Kim C.; DaPos, Stacey V.; Saul, Melissa I.; Branch, Robert A.: Outcomes assessment in routine practice: Use of an electronic medical records database, 52 (Jan)
Cooksey, Laurie J.: Focus on enbrel: A TNF-receptor blocker for treating patients with refractory rheumatoid arthritis, 211 (Mar)
Cox, Emily R.: Using decision analysis to evaluate the cost effectiveness of GP IIb/IIIa antagonists, 515 (Jun)
Cox, Emily R.; Griffis, Deborah L.: Critical evaluation of a cost-effectiveness analysis of four HMG-CoA reducatase inhibitors, 1041 (Dec)
Cunha, Burke A.: Antibiotic resistance: Myths, truths, and a rational formulary approach, 664 (Aug)

D

DaPos, Stacey V.: See Coley, Kim C.
Dedrick, Steve; Kessler, John M.: Formulary evaluation teams: Duke University Medical Center's approach to P & T Committee reorganization, 47 (Jan)
Dicks, Robert S.: See White, C. Michael
Domenichini, David: See Amato, Paul V.
Dragon, Cathy: See Tangalos, Eric G.
Drusano, George L.: See Preston, Sandra L.
Dunn, Alisha; Chow, Moses S.S.; Kluger, Jeffrey: Focus on nesiritide: A natriuretic peptide with hemodynamic benefits in patients with acute decompensated CHF, 123 (Feb)
Dunn, Erin C.; Small, Ralph E.: Focus on leflunomide: An immunomodulatory agent for the treatment of rheumatoid arthritis, 21 (Jan)

E

Esposito, Maria: See Stirling, Alexandra L.

F

Fendrick, A. Mark; Blitz, Susan G.: Gastroesophageal reflux: Therapy considerations after failure of low-dose, nonprescription H_2RAs, 234 (Mar)
Feret, Brett; Quercia, Robert A.; Cappa, Joseph: Focus on rabeprazole: A proton pump inhibitor for the treatment of acid-related disorders, 313 (Apr)
Feret, Brett; Quercia, Robert A.: Focus on ebastine: A once-daily nonsedating antihistamine for the treatment of allergic rhinitis, 645 (Aug)
Finley, Patrick R.; Rens, Heidi R.; Gess, Susan; Louie, Clifton: Case management of depression by clinical pharmacists in a primary care setting, 864 (Oct)

G

Galant, Stanley P.; Wilkinson, Robert: Allergic rhinitis: An assessment of current pharmacotherapeutic options,1016 (Dec)
Gess, Susan: See Finley, Patrick R.
Griffis, Deborah L.: See Cox, Emily R.
Guay, David R.P.: An evaluation of interferon in the treatment of hepatitis C virus infection, 132 (Feb)
Gutierrez, Mary A.; Stimmel, Glen L.; Yi, Donna D.: Focus on reboxetine: A selective norepinephrine reuptake inhibitor for the treatment of major depression, 909 (Nov)

H

Hunter, Walter J.: See Shaw, Sonia V.

J

Jacobson, Edwin J.: See Black, Henry R.
Jarawan, Salim: See Poindexter, Maha
Johnson, Nelda:
Assessing and reporting outcomes of a disease management program, 455 (May)
Evaluating the quality and applicability of database-derived outcomes studies, 603 (Jul)
The future of outcomes management: Views from thought leaders in the field, 776 (Sep)
Translating and implementing outcomes research into clinical practice, 251 (Mar)
Where to find outcomes information: A guide to useful Internet sites, 953 (Nov)

K

Kelly, Patrick C.: See Whaley, David L.
Kessler, John M.: See Dedrick, Steve
Kluger, Jeffrey:
See Dunn, Alisha
See Tsikouris, James P.

L

Leach, Terry; Rushnak Michael: Revamping P & T Committee structure and process: Use of a physician-driven approach, 341 (Apr)
Lehman, Mark E.: See Tangalos, Eric G.
Louie, Clifton: See Finley, Patrick R.

M

Maas, Barbara: See Stirling, Alexandra L.
Mackersie, Robert C.: Toward the rational use of

Author Index to Volume 34, 1999

antibiotics in the intensive care unit, 836 (Oct)
Mahnke, C. Becket: See Whaley, David L.
Mason, Alan: See Tangalos, Eric G.
Motheral, Brenda; Bataoel, James R: A strategy for evaluating the novel COX-2 inhibitors versus NSAIDs for arthritis, 855 (Oct)
Motheral, Brenda: Critical evaluation of a decision-analytic model of ulcer treatment, 355 (Apr)

N

Nash, David B.: The case for covering Rx-to-OTC switch products: The H_2-receptor antagonist example, 452 (May)
Nostrant, Timothy T.: See Stern, Mark A.

P

Poindexter, Maha; Jarawan, Salim: Development and implementation of albumin-use guidelines in a community hospital, 151 (Feb)
Preston, Sandra L.; Drusano, George L.: Focus on gatifloxacin: A new fluoroquinolone for use in community-acquired pneumonia and other infections, 1002 (Dec)

Q

Quercia, Robert A.: See Feret, Brett

R

Raymond, Joanne: Use of pharmacologic agents to treat concomitant hypertension and BPH, 220 (Mar)
Reddy, Prabashni; Ross, Jack: Focus on amprenavir: A protease inhibitor for the treatment of patients with HIV-1 infection, 567 (Jul)
Rens, Heidi R.: See Finley, Patrick R.
Rihn, Thomas L.: See Vanscoy, Gordon J.
Ross, Jack: See Reddy, Prabashni
Ross, Mary B.: See Smith, Melissa A.
Rothman, Alan: See Stirling, Alexandra L.
Rushnak, Michael: See Leach, Terry

S

Sanoski, Cynthia A.: See Aull, Meredith J.
Saul, Melissa I.: See Coley, Kim C.
Schneider, Alan L.: SSRI therapy for depression: Assessing overall treatment costs and cost drivers, 578 (Jul)
Schrand, Linda M.: Recent additions to the growing biotechnology armamentarium: A critical assessment, Part 1, 920 (Nov)
Shaw, Sonia V.; Hunter, Walter J.; Shirer, Alyson E.: Selection and dosing of nitrates to avoid tolerance during sustained antianginal therapy, 590 (Jul)
Shirer, Alyson E.: See Shaw, Sonia V.
Small, Ralph E.: See Dunn, Erin C.
Smith, Melissa A.; Ross, Mary B.: Oral 5-HT_1 receptor agonists for migraine: Comparative considerations, 324 (Apr)
Steinberg, Martin: Pharmacologic treatment of Alzheimer's disease: An update on approved, unapproved therapies, 32 (Jan)
Stern, Mark A.; Nostrant, Timothy T.: *Helicobacter pylori:* Diagnosis and treatment update, 654 (Aug)
Stimmel, Glen L.: See Gutierrez, Mary A.
Stirling, Alexandra L.; Belliveau, Paul; Maas, Barbara; Rothman, Alan; Bercume, Roland; Esposito, Maria: Experience with a decentralized IV to PO ofloxacin conversion program, 688 (Aug)

T

Tangalos, Eric G.; Lehman, Mark E.; Baran, Robert; Dragon, Cathy; Warshaw, Gregg; Mason, Alan: Developing geriatric-specific pharmacotherapy guidelines: Insights and challenges, 764 (Sep)
Tanner, Jill: See Whaley, David L.
Tomich, David J.: See Whaley, David L.
Tsikouris, James P.; Kluger, Jeffrey: Focus on azimilide: A nonselective class III antiarrhythmic agent for use in atrial fibrillation, 737 (Sep)

V

Vanscoy, Gordon J.; Rihn, Thomas: GP IIb/IIIa receptor inhibitors: Clinical and cost considerations in acute coronary syndromes, 500 (Jun)

W

Warshaw, Gregg: See Tangalos, Eric G.
Wechsler, Jill:
Clinton calls for PBMs to administer universal Medicare drug benefit, 712 (Aug)
Congress focuses on formulary practices vis-á-vis patients' rights, Medicare+Choice, 794 (Sep)
Controversy over prescription drug advertising stimulates policy changes, 878 (Oct)
Drug safety concerns focus attention on postmarketing surveillance, medication errors, 373 (Apr)
FDAMA implementation policies to spur drug development, streamline FDA approval process, 176 (Feb)
FDA pursues new policy on dietary supplements amid calls for more information, regulation, 972 (Nov)
FDA's pediatric labeling initiatives seek to end children's 'therapeutic orphan' status, 534 (Jun)
FDA struggles over policies affecting PBMs and Internet marketing, 1054 (Dec)
Medicare drug benefit debate highlights formularies, pharmacy benefit managers, 289 (Mar)
Online pharmacies draw regulators' attention and generate professional concerns, 468 (May)
Pharmaceutical prices, reform of managed care and Medicare top policy agenda for 1999, 80 (Jan)
Pharmacists, health organizations map plans to ensure systems, supplies are ready for Y2K, 620 (Jul)
Whaley, David L.; Tomich, David J.; Kelly, Patrick C.; Tanner, Jill; Mahnke, C. Becket: Impact of clinical pharmacist-led guideline enforcement on drug costs, patient satisfaction, 257 (Mar)
White, C. Michael; Dicks, Robert S.: Focus on rivastigmine: An acetylcholinesterase inhibitor for patients with Alzheimer's disease, 493 (Jun)
Wilkinson, Robert: See Galant, Stanley P.

Y

Yi, Donna D. See Gutierrez, Mary A.

Appreciation to Our Reviewers

Fifty-four health care professionals served as external reviewers for manuscripts submitted to Formulary from November 1998 through October 1999. The *Formulary* staff editors express appreciation to these reviewers who have helped to maintain quality and consistency in the published articles.

Michael L. Adams, RPh, PhD
Cristina Bello, PharmD
Paul Beringer, PharmD
Crystal S. Blankenship, PharmD
Brenda V. Borders-Hemphill, PharmD
John D. Butts, PharmD
Wesley G. Byerly, PharmD
Derek Chaudhary, MHSA
Moses S. S. Chow, PharmD
Novena T. Chui, PharmD
Kim C. Coley, PharmD
Scott Conry, PharmD, RPh
Irene Contreras, PharmD
Burke A. Cunha, MD
Steven Erickson, PharmD
Jacqueline L. Fein, PharmD
Carla B. Frye, PharmD
Eric Harvey, PharmD, MBA
Richard M. Hellman, MD
Leo E. Hollister, MD
Michele B. Kaufman, PharmD
Michael Kendrach, PharmD
Jung Lee, PharmD
Lawrence B. Lehman, MD
Jim Lile, PharmD
George E. MacKinnon III, MS, RPh
Neil J. MacKinnon, PhD, RPh
Ann McDonald, MD
Charity McGannon, PharmD
Veronica Moriarty, PharmD
Amy Outlaw, PharmD
Paul J. Oesterman, PharmD
Laura Opincar
David Parra, PharmD
Mark Pugh, PharmD
Robert A. Quercia, MS
Richard Quintiliani, MD
Mary B. Ross, RPh, MBA
Jerome M. Sampson, MD
Gary E. Sander, MD, PhD
Maureen E. Savitsky, PharmD
Linda Schrand, PharmD
Brian M. Schwartz, MD
Stephen D. Sears, MD
Charles C. Sharkey, MS, RPh
Gary E. Stein, PharmD
Craig S. Stern, PharmD, MBA
F. Randy Vogenberg, RPh, PhD
Terry Walker, PharmD
Elizabeth Welter, RPh
Albert I. Wertheimer, PhD
C. Michael White, PharmD
Steven R. Wirebaugh, PharmD
James M. Wooten, PharmD